Advanced Memory Research Institute of NJ

Toms River, New Jersey 08755

0 studies enrolling now · 17 studies all time

What they study most

Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer's Disease, Cognitive Dysfunction, Dementia, Early Alzheimer's Disease, Early Alzheimer´s Disease

Studies at this site

• PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) — Running, not enrolling
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) — Completed
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) — Completed
• A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease — Stopped early
• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease — Stopped early
• Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease — Stopped early
• Open-label Extension for Phase 3 Clinical Trials of Simufilam — Stopped early
• A Study of Semorinemab in Patients With Moderate Alzheimer's Disease — Completed
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
• Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD — Completed
• A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease — Stopped early
• Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease — Stopped early
• A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) — Stopped early
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease — Stopped early
• Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease — Status unconfirmed